Insider buying last 90 days
No open-market insider purchases were filed for ZBH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ZBH insider filing, plotted on the chart in Gekko.Open ZBH in Gekko
NYSE: ZBH
Zimmer Biomet (ZBH) Stock Analysis & Forecast
Sep 28 close
$91.62+0.58 (+0.6%)
Gekko Brief
AI summaryZimmer Biomet's week centers on leadership changes effective October 1, including new regional and business-unit presidents, alongside a reiteration of full-year 2026 guidance. The company also declared a quarterly dividend of $0.24 per share, payable 30 October, while BMO Capital reiterated a Market Perform rating and a $96.00 price target, citing the opportunity from the company's iodine-coated hip implant launch in Japan. Separately, second-quarter 2026 results showed adjusted EPS of $2.07 and revenue of $2.18 billion, both ahead of analyst estimates, alongside raised full-year guidance, though the stock fell 1.31% that session; other sessions saw the shares trade near $91.57 and $91.04.
Shares closed at $91.62, up 0.6%, sitting between the 50-day average of $96.09 and the 200-day average of $91.40, a mixed trend picture. The GekkoIndex reads 64.7, placing the stock in the Accumulation zone. Price sits 42.6% below Gekko Fair Value of $159.63.
The next earnings report is scheduled for 4 November 2026, 36 days out and beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the current window. Seasonality over the next 20 trading days has averaged -1.3% across 5 years, with gains in 2 of those years. Consensus among 18 covering firms includes 6 buy and 12 hold ratings, with no sell ratings, and a consensus target of $107.57.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Zimmer Biomet price vs fair value
Close $91.62200-day averageGekko Fair Value $159.63
Zimmer Biomet quick facts
- Market cap
- $17.72B
- P/E ratio
- 21.8
- Forward P/E
- 10.1
- EPS, TTM
- $4.12
- Revenue, TTM
- $8.51B
- Profit margin
- 9.5%
- Dividend yield
- 1.06%
- Beta
- 0.47
- Volume
- 1.49M avg 2.03M
- 1-year return
- −5.5%
- Typical daily move
- ±3%
- Typical 20-day move
- ±4.5%
- 50-day average
- $96.09
- 200-day average
- $91.40
- Next earnings
- Nov 4 before open
- Shares outstanding
- 190.7M
Zimmer Biomet swing-trade checklist
Zimmer Biomet scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $91.62 sits between the 50-day ($96.09) and 200-day ($91.40) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.7, Accumulation
Reading 64.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
42.6% below
Price is 42.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.3% on average
From this point in the calendar, the next 20 trading days averaged −1.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Zimmer Biomet stock chart and price history
Zimmer Biomet closed at $91.62 on Sep 28, 2026, −5.5% over the past year, inside a 52-week range of $79.12 to $106.88.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.9%
- 3 months
- +0.4%
- 6 months
- +3.4%
- 1 year
- −5.5%
The full ZBH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ZBH in Gekko
Follow Zimmer Biomet through every session
Put ZBH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ZBH in GekkoFree for 7 days. No credit card required.
About Zimmer Biomet
Zimmer Biomet develops, produces, and sells devices used in orthopedic reconstruction, the kind of surgery that repairs or replaces joints. Alongside these core products, it makes items for sports medicine, biologics, extremities and trauma care, spine and craniomaxillofacial and thoracic treatment, dental implants, office-based technology, and other surgical tools, serving hospitals and medical practices that rely on these products in patient care.
The business is structured around three geographic segments. The Americas segment covers the United States along with other markets across North, Central, and South America. The Europe, Middle East and Africa segment includes countries such as France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment spans markets including Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia.
Zimmer Biomet traces its founding to Justin O. Zimmer in 1927 and keeps its headquarters in Warsaw, Indiana. Its shares are listed on the NYSE under the ticker ZBH.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- zimmerbiomet.com
Zimmer Biomet GekkoIndex: the smart money zone
Zimmer Biomet’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.7, in the Accumulation zone, up 4.1 points over five sessions.
64.7Accumulation
Up 4.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +1.2% | +1.1% | ||
| Accumulation (current zone) | 280 | +0.5% | +1.0% | ||
| Neutral | 333 | −0.9% | −1.9% | ||
| Distribution | 12 | −0.6% | −7.6% | ||
| Selling | 1 | Too few readings yet | |||
Average ZBH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ZBH price, zone by zone.Track ZBH in Gekko
Is Zimmer Biomet stock overvalued? Gekko Fair Value
Zimmer Biomet trades 42.6% below Gekko Fair Value of $159.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Zimmer Biomet shares are worth, recalculated every trading day.
$159.63
Gekko Fair Value, Sep 26, 2026
42.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ZBH in Gekko
Zimmer Biomet insider and Congress trading
No open-market insider purchases were filed for Zimmer Biomet, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ZBH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ZBH, plotted on the chart in Gekko.Open ZBH in Gekko
Buybacks
Zimmer Biomet has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $250.7M
- As a share of market cap
- 1.41%
- Trailing four quarters
- $987.8M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ZBH.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Zimmer Biomet earnings: next date and track record
Zimmer Biomet reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $1.89
- Revenue estimate
- $2.04B
7 of 8reports beat the EPS estimate
±7.9%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Apr 28, 2026 AI summary
- What they said
- Zimmer Biomet reported Q1 2026 organic constant currency revenue growth of 2.9%, at the upper end of annual guidance. Adjusted EPS of $2.09 rose 15% year-over-year, including a $0.20 tariff-related benefit. U.S. business grew 3.2% with hips up 5% and knees up 2.2%; technology/data/bone cement segment grew nearly 12%. Partial knee sales surged over 20%, and the ROSA/TMINI robotic platforms continue gaining traction.
- Guidance
- Full year 2026 organic constant currency revenue growth guidance range not explicitly restated in excerpt, but Q1 performance came in at the upper end of annual targets. Management reaffirmed commitments to 2026 sales growth, EPS, and free cash flow goals.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 28, 2026 | $2.09 est $1.86 | $2.09B est $2.07B | −13.5% |
| Feb 10, 2026 | $2.42 est $2.40 | $2.24B est $2.22B | +6.6% |
| Nov 5, 2025 | $1.90 est $1.88 | $2.00B est $2.01B | −14.2% |
| Aug 7, 2025 | $2.07 est $1.98 | $2.08B est $2.06B | +8.9% |
| May 5, 2025 | $1.81 est $1.77 | $1.91B est $1.90B | −9.9% |
| Feb 6, 2025 | $2.31 est $2.29 | $2.02B est $2.01B | −6.8% |
| Oct 30, 2024 | $1.74 est $1.74 | $1.82B est $1.80B | +2.9% |
| Aug 7, 2024 | $2.01 est $1.99 | $1.94B est $1.94B | −0.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Zimmer Biomet stock forecast and analyst price targets
Analysts’ average 12-month price target for Zimmer Biomet is $107.57, +17.4% from the last close, from 18 firms rating the stock in the last 90 days.
$107.57consensus 12-month target, +17.4% from the last close
Now $91.62Avg $107.57
Low $93High $120
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Bank of America Securities | $110 | +20.1% |
| Sep 16 | Truist Financial | $106 | +15.7% |
| Sep 9 | Truist Financial | — | — |
| Sep 8 | Bank of America Securities | $110 | +20.1% |
| Aug 17 | J.P. Morgan | $117 | +27.7% |
+1.0%average 20-day move after past Accumulation readings
−1.3%average move over the next 20 trading days in the last 5 years
±3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Zimmer Biomet seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Zimmer Biomet averaged −1.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.5% | 2 of 5 |
| Next 10 trading days | −3.4% | 1 of 5 |
| Next 15 trading days | −0.9% | 2 of 5 |
| Next 20 trading days | −1.3% | 2 of 5 |
| Next 30 trading days | −4.2% | 1 of 5 |
For scale, ZBH’s typical 20-trading-day move in either direction is about 4.5%.
Zimmer Biomet market cap and key statistics
Zimmer Biomet’s market cap is $17.72B, with a P/E ratio of 21.8 and revenue of $8.51B over the last twelve months.
Valuation
- Market cap
- $17.72B
- P/E ratio
- 21.8
- Forward P/E
- 10.1
- EPS, TTM
- $4.12
- Gekko Fair Value
- $159.63
Trading
- Volume
- 1.49M
- Avg volume, 20 days
- 2.03M
- 52-week high
- $106.88
- 52-week low
- $79.12
- Shares outstanding
- 190.7M
Financials
- Revenue, TTM
- $8.51B
- Profit margin
- 9.5%
- Return on equity
- 6.4%
- Quarterly earnings growth, YoY
- +33.8%
Risk and income
- Beta
- 0.47
- Typical daily move
- ±3%
- Typical 20-day move
- ±4.5%
- Dividend yield
- 1.06%
Zimmer Biomet stock news this week
Coverage of Zimmer Biomet this week reads positive: 6 positive, 4 neutral and 3 negative headlines.
- Zimmer Biomet stock closes at USD 91.04 on September 25, 2026AD HOC NEWS, Sep 28
- What Changed for Zimmer Biomet (NYSE:ZBH) After Dividend Update?Kalkine Media, Sep 28
- BMO reiterates Zimmer Biomet stock rating on Japan hip implant opportunityInvesting.com Canada, Sep 28
- Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly DividendMarketBeat, Sep 28
- Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?Yahoo Finance UK, Sep 26
- Zimmer Biomet stock trades at USD 91.57, up 2.10 percent in New York tradingAD HOC NEWS, Sep 25
Zimmer Biomet peers
Zimmer Biomet’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Zimmer Biomet stock FAQ
What is Zimmer Biomet’s market cap?
Zimmer Biomet’s market cap is $17.72B at the Sep 28, 2026 close of $91.62, with 190.7M shares outstanding. The shares trade on a P/E ratio of 21.8.
What is the Zimmer Biomet stock forecast?
The consensus analyst 12-month price target for Zimmer Biomet is $107.57, +17.4% from the last close. Of the 18 firms that rated the stock in the last 90 days, 6 rate it a buy, 12 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Zimmer Biomet stock overvalued or undervalued?
On Gekko’s estimate Zimmer Biomet is undervalued: the Sep 28, 2026 close of $91.62 is 42.6% below Gekko Fair Value of $159.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Zimmer Biomet report earnings next?
Zimmer Biomet is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $1.89 per share on revenue of $2.04B. Zimmer Biomet beat the earnings estimate in 7 of its last 8 reports, moving 7.9% on average across the report.
What is Zimmer Biomet’s 52-week high and low?
Zimmer Biomet’s 52-week high is $106.88 and its 52-week low is $79.12; it closed at $91.62 on Sep 28, 2026, −5.5% over the past year. Over the last five years the shares peaked at $149.25 on May 2, 2023.
Is Zimmer Biomet stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Zimmer Biomet the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.